Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the renewal of its property and equipment lease agreements with Kelun Pharmaceutical. The new agreements, effective from January 1, 2025, to December 31, 2027, are considered connected transactions as Kelun Pharmaceutical is a controlling shareholder. These transactions are treated as acquisitions of capital assets under the Listing Rules, requiring reporting and announcement but not independent shareholder approval. Multiple directors abstained from voting due to conflicts of interest.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
YTD Price Performance: -1.84%
Average Trading Volume: 303,282
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$37.59B
See more data about 6990 stock on TipRanks’ Stock Analysis page.
